Lung damage

Lung damage refers to the structural and functional impairment of the respiratory system's tissues, specifically affecting the alveoli, bronchioles, and pulmonary vasculature. It is a complex pathological state resulting from various insults, including environmental toxins (e.g., cigarette smoke, pollutants), infectious agents (e.g., SARS-CoV-2, influenza), or autoimmune responses. This condition is characterized by the breakdown of the alveolar-capillary barrier, leading to impaired gas exchange, inflammation, and potentially permanent remodeling such as fibrosis. In the context of drug development, lung damage is considered a clinical endpoint or a disease manifestation rather than a discrete molecular target like a receptor or enzyme. While numerous therapeutic interventions aim to prevent or repair lung damage, they do so by targeting specific signaling pathways—such as the TGF-beta pathway in fibrosis or cytokine cascades in acute injury—rather than the 'damage' itself. Consequently, this entry represents a phenotypic outcome of disease rather than a druggable protein or nucleic acid sequence.

Other names

Lung injuryPulmonary damagePulmonary injuryLung parenchyma damageAcute lung injury

Not applicable as this is a pathological condition/phenotype rather than a specific molecular target.